hepatitis C drugs

Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Safety Concerns Over Some Hepatitis C DrugsThe ISMP has issued a report that links several direct-acting antiviral agents for hepatitis C to serious adverse side effects. But drug makers take issue.
Watch list 2017: Top therapeutic areas
Watch list 2017: Top therapeutic areasFind out about the latest treatment and drug pipeline developments
Former Walgreens manager to be sentenced in fraud caseThe charges involve falsified claims for expensive hepatitis C medications.
AbbVie hep C drug combo enters marketIn an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).
PBM giants pare down drug expenses
PBM giants pare down drug expensesWhen Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
AbbVie to profit from new Viekira Pak usesFDA expanded the use of ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets without ribavirin (Viekira Pak, AbbVie) this week to treat patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A).